Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neutralizing antibodies for the PD-1/PD-L1 interaction or for CTLA4 restores the cytotoxic activity of T-cells, which induces T-cell mediated tumor cell destruction, and have transformed the cancer treatment landscape (Table 1) [82].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [82]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“Since highly mutated tumors show a favorable response to therapy, more insight is needed at the gene level to determine the mutations which are proresponsive and thus have the potential to be used as predictive biomarkers [107].”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“In the management of advanced metastatic melanoma, pembrolizumab has improved the overall survival of patients, with relatively minimal toxicity [44].”
BackgroundGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Similar findings were observed in the gut microbiome profile of patients with hepatocellular carcinoma (HCC) [109] and melanoma [110] who were treated with anti-PD-1 immunotherapy.”
ResultPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Research works printed but not linked: 1
- Z. R. Kelly, 2019, The Financial and Physical Toxicity of Immune Checkpoint Inhibitors in Cancer Alexandria
Cited by
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Cui, J.-W., Li, Y., Yang, Y., Yang, H.-K., Dong, J.-M., Xiao, Z.-H., He, X., Guo, J.-H., Wang, R.-Q., Dai, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116203 · Cited by 184
Rizzo, A., Ricci, A. D., Federico, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803133 · Cited by 110
Evolution of cell therapy for renal cell carcinoma
Wang, Y., Suarez, E. R., Kastrunes, G. M., de Campos, N. S. P., Abbas, R., Pivetta, R. S., Murugan, N., Chalbatani, G. M., D’Andrea, V. D., & Marasco, W. A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01911-x · Cited by 126
Eosinophils in the tumor microenvironment: implications for cancer immunotherapy
Ghaffari, S., & Rezaei, N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04418-7 · Cited by 128
Self-citationRizzo, A., & Ricci, A. D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1972969 · Cited by 105
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 108
Foster, S. L., Woolsey, C. B., Borisevich, V., Agans, K. N., Prasad, A. N., Deer, D. J., Geisbert, J. B., Dobias, N. S., Fenton, K. A., Cross, R. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200065119 · Cited by 78
Grenda, A., Iwan, E., Chmielewska, I., Krawczyk, P. A., Giza, A., Bomba, A., Frąk, M., Rolska-Kopińska, A., Szczyrek, M., Kieszko, R., et al. (2022) · AMB Express · doi:10.1186/s13568-022-01428-4 · Cited by 71
Parkinsonism in viral, paraneoplastic, and autoimmune diseases
Xing, F., Marsili, L., & Truong, D. D. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120014 · Cited by 63
Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 63
Lin, X., He, T., Tang, R., Li, Q., Wu, N., Zhou, Y., He, H., Wan, L., Huang, J., Jiang, Q., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01287-y · Cited by 60
Gao, Y., Xu, Q., Li, X., Guo, Y. L., Zhang, B., Jin, Y., Zhu, C., Shen, Y., Yang, P., Shi, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04654-7 · Cited by 47
Wu, S., Lin, K., Lawal, B., Wu, A. T. H., & Wu, C. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.047 · Cited by 45
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Zheng, J., Shao, M., Yang, W., Ren, J., Chen, X., & Yang, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109244 · Cited by 48
Artificial intelligence in oncologic imaging
Chen, M., Terzic, A., Becker, A. S., Johnson, J. M., Wu, C. C., Wintermark, M., Wald, C., & Wu, J. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100441 · Cited by 46
The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
Aghbash, P. S., Hemmat, N., Baradaran, B., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., & Baghi, H. B. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026776 · Cited by 41
Dai, L., Tao, Y., Shi, Z., Liang, W., Hu, W., Xing, Z., Zhou, S., Guo, X., Fu, X., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881801 · Cited by 37
Logghe, T., van Zwol, E., Immordino, B., den Cruys, K. V., Peeters, M., Giovannetti, E., & Bogers, J. (2024) · Cancers · doi:10.3390/cancers16030505 · Cited by 42
An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects
Zhao, L., Luo, H., Ma, Y., Zhu, S., Wu, Y., Lu, M., Yao, X., Liu, X., & Chen, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204114119 · Cited by 29
Devi, S., Singh, S. D., Joga, R., Patil, S. Y., Devi, V. M., Dushantrao, S. C., Dwivedi, F., Jindal, D. K., Jindal, D. K., Singh, C., et al. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114323 · Cited by 29
Ferrari, C., Maggialetti, N., Masi, T., Nappi, A. G., Santo, G., Asabella, A. N., & Rubini, G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030217 · Cited by 25
Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 26
Huang, D., Ke, L., Cui, H., & Su, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-10960-w · Cited by 26
PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
Mu, S., Liang, Z., Wang, Y., Chu, W., Chen, Y., Wang, Q., Wang, G., & Wang, C. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.754 · Cited by 23
The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment
Salim, N. H. M., Mussa, A., Ahmed, N., Ahmad, S., Yean, C. Y., Hassan, R., Uskoković, V., Mohamud, R., & Jalil, N. A. C. (2023) · Biomedicines · doi:10.3390/biomedicines11010173 · Cited by 21
Liu, K., Cui, L., Li, C., Tang, C., Niu, Y., Ji, H., Bu, Y., & Chen, B. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.922472 · Cited by 22
PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
Alkaabi, D., Arafat, K., Sulaiman, S., Al-Azawi, A. M., & Attoub, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076420 · Cited by 22
“Drug-Free” chitosan nanoparticles as therapeutic for cancer treatment
Iskandar, A., Kim, S., & Wong, T. W. (2024) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2024.2323943 · Cited by 21
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
Li, H.-Y., Chen, Y., Deng, X., Li, H., Tan, J., Liu, G., Zheng, Y., Pei, M., Peng, K.-T., Yue, L.-L., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01118-2 · Cited by 23
Cai, X., Yin, G., Chen, S., Tacke, F., Guillot, A., & Liu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03351-z · Cited by 24
Eskafi, A. H., Oghalaei, A., Mahboudi, F., Ghaderi, H., Behdani, M., Shoari, A., & Kazemi‐Lomedasht, F. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2131571 · Cited by 17
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00568 · Cited by 21
Inhibitory immune checkpoints in cancer immunotherapy
Tang, Z.-H., & Veillette, A. (2025) · Science Immunology · doi:10.1126/sciimmunol.adv6870 · Cited by 18
Que, Y., Wang, J., Sun, F., Wang, S., Zhu, J., Huang, J., Zhao, Z., Zhang, L., Liu, J., Xu, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01636-9 · Cited by 17
HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma
Liao, X., & Zhang, D. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab221 · Cited by 15
Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging
Liang, Z., Hu, X., Hu, H., Wang, P., & Cai, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1017737 · Cited by 15
Shi, H., Zhang, W., Zhang, L., Zheng, Y., & Dong, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265202 · Cited by 22
Wang, C., Wang, Z., Zhao, Y., & Wang, F. (2023) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2023.23.e17 · Cited by 13
Yu, B., Liu, Y., Chen, X., Zhang, W., Cen, Y., Yan, M., Liu, Q., & Li, S. (2024) · Small · doi:10.1002/smll.202311507 · Cited by 13
A pan-cancer analysis reveals the genetic alterations and immunotherapy of Piezo2 in human cancer
Liu, X. Z., Jia, Y., Wang, Z., Zhang, Z., & Fu, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918977 · Cited by 15
Tahir, I. M., Rauf, A., Mehboob, H., Sadaf, S., Alam, M. S., Kalsoom, F., Bouyahya, A., Allam, A. E., Omari, N. E., Bakrim, S., et al. (2022) · Human Antibodies · doi:10.3233/hab-220001 · Cited by 12
Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R. (2025) · Molecules · doi:10.3390/molecules30132686 · Cited by 15
Rovers, S., Janssens, A., Raskin, J., Pauwels, P., van Meerbeeck, J. P., Smits, E., & Marcq, E. (2022) · Biomedicines · doi:10.3390/biomedicines10030673 · Cited by 13
Zheng, B., Wang, H., Zhai, S., Li, J., & Lu, K. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101542 · Cited by 14
Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
Xie, P., Liu, J., Yan, H., Wang, Z., Jiang, S., Li, X., & Liu, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950831 · Cited by 12
Hu, B., Huang, J., Niu, K., Zhou, J., Wang, N.-N., Liu, Y., & Chen, L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175746 · Cited by 11
The Role of Ketogenic Diet in the Treatment of Neuroblastoma
Makuku, R., Far, Z. S., Khalili, N., Moyo, A., Razi, S., Keshavarz‐Fathi, M., Mahmoudi, M., & Rezaei, N. (2023) · Integrative Cancer Therapies · doi:10.1177/15347354221150787 · Cited by 13
Self-citationEstablishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor
Puopolo, T., Li, H., Gutkowski, J., Cai, A., Seeram, N. P., Ma, H., & Liu, C. (2023) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4765 · Cited by 10
Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations
Babar, Q., Saeed, A., Murugappan, S., Dhumal, D. M., Tabish, T. A., & Thorat, N. D. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103577 · Cited by 14
Chan, H., Trout, C. V., Mikolon, D., Adams, P. L., Guzman, R. Z., Mavrommatis, K., Abbasian, M., Hadjivassiliou, H., Dearth, L. R., Fox, B. A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0634 · Cited by 11
Zhang, K., Tao, Y., & Wang, F. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf008 · Cited by 9
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
AlKhazal, A., Chohan, S., Ross, D. J., Kim, J., & Brown, E. G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553511 · Cited by 13
Verhoef, J. I., Klont, E., van Overveld, F. J., & Rijkers, G. T. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2262765 · Cited by 9
Novel Therapies for Tongue Squamous Cell Carcinoma Patients with High-Grade Tumors
Li, Y., Lin, H., Chen, L., Chen, Z., & Li, W. P. (2021) · Life · doi:10.3390/life11080813 · Cited by 9
Advances of ultrasound in tumor immunotherapy
Lin, J., Wu, Y., Liu, G., Cui, R., & Xu, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112233 · Cited by 9
Pousse, L., Manchala, A., Klein, C., & Deak, L. C. (2025) · mAbs · doi:10.1080/19420862.2025.2590250 · Cited by 11
Saftawy, E. A. E., Turkistani, S. A., Alghabban, H. M., Albadawi, E. A., Ibrahim, B. E., Morsy, S. A. A., Farag, M. F., AlHariry, N. S., Shash, R. Y., Elkazaz, A., et al. (2023) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2023.e00201 · Cited by 9
Baldi, S., Alnaggar, M., AL-Mogahed, M., Khalil, K., & Zhan, X. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00403-w · Cited by 8
The role of immune checkpoint molecules in cancers
Zhang, M., Xu, J., Zheng, Z., Guo, Z., Wang, H., Zhou, M., Tang, H., & Zhu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1674818 · Cited by 18
Adugna, A., Muche, Y., Jemal, M., Habtegiorgis, S. D., Belew, H., & Amare, G. A. (2024) · Aging Medicine · doi:10.1002/agm2.12292 · Cited by 6
Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies
Ward, M. B., Jones, A. B., & Krenciute, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001070 · Cited by 8
Makuku, R., Seyedmirzaei, H., Tantuoyir, M. M., Rodríguez‐Román, E., Albahash, A., Mohamed, K., Moyo, E., Ahmed, A. O., Razi, S., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108580 · Cited by 8
Self-citationDomingo-Contreras, E., Tormo, J. R., González-Menéndez, V., Mackenzie, T. A., Martı́n, J., Magiera‐Mularz, K., Kitel, R., Reyes, F., Genilloud, O., Fernández‐Godino, R., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130458 · Cited by 6
Makrantonakis, A.-E., Zografos, E., Gazouli, M., Dimitrakakis, K., Toutouzas, K. G., Zografos, C. G., Kalapanida, D., Tsiakou, A., Samelis, G., & Zagouri, F. (2022) · Medicina · doi:10.3390/medicina58101399 · Cited by 8
Waqas, M. S., Halim, S. A., Alsalman, A., Khan, A., Elkord, E., & Al‐Harrasi, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2188958 · Cited by 6
Tang, C., Dong, Z., Shi, Y., Liu, B., Wang, Z., Cheng, L., Liu, F., Sun, H., Du, Y., Pan, L., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116748 · Cited by 5
Identification of SLC31A1 as a prognostic biomarker and a target for therapeutics in breast cancer
Fu, H., Dong, S., & Li, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-76162-x · Cited by 5
Framework Nucleic Acids: Innovative Tools for Cellular Sensing and Therapeutics
Zhang, Y., Li, Y., Fang, B., Du, Y., & Peng, P. (2024) · ChemBioChem · doi:10.1002/cbic.202400810 · Cited by 5
Lucena‐Sánchez, E., Hicke, F. J., Trujillo, S. C., García‐Fernández, A., & Martínez‐Máñez, R. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400004 · Cited by 5
Yadigaroglu, K., Scharf, S., Gretser, S., Schäfer, H., Deli, A. S. S., Loth, A. G., Yegoryan, H., Schmitz, R., Donnadieu, E., Hansmann, M., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284512 · Cited by 7
A Global Perspective of Cancer Prevalence: The Causative Agent, the Environment, or the Genes?
Mohamed, K., Abarikwu, S. O., Mmema, L. P., Jibril, A. T., Rahmah, L., Ivanovska, M., Rahimi, A. M., Joya, M., Hashem, F., Essouma, M., et al. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_100-1 · Cited by 8
Self-citationImmunotherapies in breast cancer: harnessing the cancer immunity cycle
Lok, V. M., Olson-Mcpeek, S. K., Spiegelhoff, G., Cortez, J., Detz, D., & Czerniecki, B. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2427038 · Cited by 4
Zhang, F., & Wang, S. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-23-23 · Cited by 4
Wang, X., He, J. W., Sun, M., Wang, S., Qu, J., Shi, H., & Rao, B. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03553-x · Cited by 5
Singh, P., Yadav, M., Niveria, K., & Verma, A. K. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00072 · Cited by 5
Wu, B., Sun, C. M., Sun, X., & Li, X. (2022) · Medicine · doi:10.1097/md.0000000000030532 · Cited by 5
Immunotherapy and Targeted Therapy in the Management of Oral Cancers
Dutta, S., Singhal, S., Shah, R., & Haque, M. (2022) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2022046361 · Cited by 4
Rohrberg, K. S., Melero, I., Sanmamed, M. F., Muñoz‐Couselo, E., Cervantes, A. M. R., Gambardella, V., Greillier, L., Garrido, P., Kim, H. R., Lee, D. H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012729 · Cited by 3
KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer
Guo, X., Cao, H., Hu, M. Y., Wu, Y., & Li, J. (2023) · Journal of Immunology Research · doi:10.1155/2023/9542311 · Cited by 5
da Veiga, C. R. P., da Veiga, C. P., da Silva, D. M., Viana, F. G., Su, Z., & Drummond‐Lage, A. P. (2025) · Journal of Open Innovation Technology Market and Complexity · doi:10.1016/j.joitmc.2025.100543 · Cited by 5
Non-small Cell Lung Cancer, Immunotherapy and the Influence of Gut Microbiome
Raziq, M. F., Manzoor, H., & Kayani, M. U. R. (2025) · Current Microbiology · doi:10.1007/s00284-025-04408-6 · Cited by 4
Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-bpvfq · Cited by 3
Das, J., Bera, S., Ganguly, N., Guha, I., Ghosh, T., Bhuniya, A., Nandi, P. S., Chakravarti, M., Dhar, S., Sarkar, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325161 · Cited by 2
Development of a predictive model for immune‑related adverse events in patients with cancer
Tang, Y., Shi, J., Wang, L., Zhang, Y., Xu, L., & Sun, T. (2024) · Oncology Letters · doi:10.3892/ol.2024.14849 · Cited by 3
Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
Wu, M., Chen, Y., Cui, X., Yang, Q., & Xue, Q. (2023) · Medicine · doi:10.1097/md.0000000000033788 · Cited by 2
McDowell, R. C., Booth, J. D., McGowan, A., Kołodziejczyk, W., Hill, G., Banerjee, S., Feng, M., & Капуста, К. (2024) · Cancers · doi:10.3390/cancers16132295 · Cited by 2
Safizadeh, B., Sadeh, M., Robati, A. K., Riahi, T., & Tavakoli‐Yaraki, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09971-y · Cited by 2
ImmunoMet Oncogenesis: A New Concept to Understand the Molecular Drivers of Cancer
Sirajee, R., Khatib, S. E., Dieleman, L. A., Salla, M., & Baksh, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051620 · Cited by 2
Almawi, W. Y., Aimagambetova, G. N., Tursunov, A., Turesheva, A., Marat, А., Ilmaliyeva, A., & Atageldiyeva, K. K. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104524 · Cited by 2
Immune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Wu, B., Sun, C. M., Sun, X., & Li, X. (2023) · Medicine · doi:10.1097/md.0000000000034849 · Cited by 2
Potential Associations between Vascular Biology and Hodgkin’s Lymphoma: An Overview
Rodrigues, W. F., Miguel, C. B., de Abreu, M. C. M., Neto, J. M., & Oliveira, C. J. F. (2023) · Cancers · doi:10.3390/cancers15215299 · Cited by 4
Tumor-associated macrophages: Shifting bad prognosis to improved efficacy in cancer therapies?
Harlé, G., Nel, J., Corbier, C., Touche, N., & Grandemange, S. (2021) · International Journal of Immunotherapy and Cancer Research · doi:10.17352/2455-8591.000032 · Cited by 2
Protein Engineering and Drug Discovery: Importance, Methodologies, Challenges, and Prospects
Mohammed, A., Ibrahim, N. A., & Basher, N. S. (2025) · Biomolecules · doi:10.3390/biom15111628 · Cited by 1
Huang, N., & Guan, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1753660 · Cited by 1
Chen, B., Jia, Y., Meng, L., & Hu, N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1764908 · Cited by 1
Jiang, Y., Yang, Y., Wu, L., Wang, J., Wu, Y., Wang, X., Wang, H., Bai, J., Xia, X., Wang, Z., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.04.009 · Cited by 2
Metadata
- Authors
- Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N.
- Affiliations
- Universal Scientific Education and Research Network (IR)
- Iran University of Medical Sciences (IR)
- Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
- Corresponding author
- Rezaei, Nima
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2021-02-22
- Volume
- 2021
- Pages
- 1-15
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC7925068
- OpenAlex
- W3129917327
- Cited by
- 136
- References
- 169
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 33 · 2023: 29 · 2022: 29 · 2021: 11
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-1/PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy, predictive biomarkers, immune-related adverse events, autoimmune myocarditis, immunotherapy efficacy, hematologic malignancies, solid tumors
- MeSH terms
- Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Animals, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Molecular Targeted Therapy, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.